Pfizer rolls out Retacrit, a biosim to Amgen and J&J anemia blockbusters, at a big discount

This week, Pfizer launched its third biosimilar and second in two months. (Pfizer)

After experiencing slow uptake for its first biosim launch, Pfizer isn’t giving up on the budding field. On Wednesday, the drugmaker introduced its third biosim, and second in two months, launching anemia treatment Retacrit at a significant discount to Amgen’s Epogen and Johnson & Johnson’s Procrit.

Pfizer started shipping Retacrit to wholesalers on Monday at a list price of $11.03 per 1,000 units/mL, a 57% discount to Procrit and a 33.5% discount to Epogen. Together, Epogen and Procrit—which share the same active ingredient but are marketed for different uses under an Amgen-J&J licensing agreement—pulled in $1.77 billion in the U.S. last year.

The drugmaker won FDA approval for Retacrit in May after two previous complete response letters from the agency, the first seeking more data and the second over manufacturing issues.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Retacrit’s launch closely follows Pfizer’s rollout for Nivestym after an approval in July. The New York drugmaker launched Nivestym starting in October at a 30% discount to Amgen’s Neupogen, a spokesperson said. In both cases, Pfizer pointed out that the wholesale price doesn't reflect rebates and discounts.

RELATED: The top 15 drug patent expirations of 2018 - Epogen/Procrit

Pfizer’s latest pricing moves mark somewhat of a strategy shift from its Inflectra rollout, a biosimilar to Johnson & Johnson’s Remicade. The company introduced that biosimilar back in 2016 at a 15% discount to the brand. Uptake for the biosimilar has been slower than expected, and Pfizer has sued J&J for “anticompetitive” contracting to protect the brand.

In the third quarter, Inflectra generated $166 million worldwide, compared with Remicade’s $1.38 billion.

Suggested Articles

New models are needed to assess the value of gene and cell therapies and provide reimbursement, Novartis CEO Vas Narasimhan says.

With stocks tumbling and a price-fixing lawsuit hanging over its head, Mylan’s future is looking spooky. Could a new acquisition help turn the tide?

AbbVie is rolling out psoriasis drug Skyrizi after an approval last month, and it's offered Humira discounts in payer negotiations to support the launch,…